- Home
- THR vs TSHA Comparison
THR vs TSHA Comparison
Compare THR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THR
- TSHA
- Stock Information
- Founded
- THR 1954
- TSHA 2019
- Country
- THR United States
- TSHA United States
- Employees
- THR N/A
- TSHA N/A
- Industry
- THR Industrial Machinery/Components
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- THR Energy
- TSHA Health Care
- Exchange
- THR Nasdaq
- TSHA Nasdaq
- Market Cap
- THR 887.4M
- TSHA 728.4M
- IPO Year
- THR 2011
- TSHA 2020
- Fundamental
- Price
- THR $27.00
- TSHA $2.46
- Analyst Decision
- THR
- TSHA Strong Buy
- Analyst Count
- THR 0
- TSHA 7
- Target Price
- THR N/A
- TSHA $7.57
- AVG Volume (30 Days)
- THR 254.1K
- TSHA 4.9M
- Earning Date
- THR 08-06-2025
- TSHA 08-11-2025
- Dividend Yield
- THR N/A
- TSHA N/A
- EPS Growth
- THR 3.97
- TSHA N/A
- EPS
- THR 1.57
- TSHA N/A
- Revenue
- THR $498,207,000.00
- TSHA $7,224,000.00
- Revenue This Year
- THR $6.11
- TSHA N/A
- Revenue Next Year
- THR $5.40
- TSHA N/A
- P/E Ratio
- THR $17.25
- TSHA N/A
- Revenue Growth
- THR 0.72
- TSHA N/A
- 52 Week Low
- THR $23.05
- TSHA $1.05
- 52 Week High
- THR $34.36
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- THR 45.87
- TSHA 45.90
- Support Level
- THR $26.92
- TSHA $2.48
- Resistance Level
- THR $27.70
- TSHA $2.66
- Average True Range (ATR)
- THR 0.62
- TSHA 0.21
- MACD
- THR -0.03
- TSHA -0.06
- Stochastic Oscillator
- THR 53.19
- TSHA 10.14
About THR Thermon Group Holdings Inc.
Thermon Group Holdings Inc is a United States-based company that provides engineered thermal solutions for process industries. The company's product portfolio comprises electric heat tracing cables, steam tracing components, tubing bundles, and instrument and control products, as well as complementary product lines. It also provides turnkey services and design and engineering services. The company's customers include large engineering, procurement, and construction companies; oil and gas companies; commercial subcontractors; electrical component distributors; and others. The company has a presence, with the United States, Canada, and Europe being its top three markets and contributing the majority of its sales.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.